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Background: Mounting evidence indicates that herbal therapy is effective in alleviating 
anxiety, lessening cancer treatment-related side-effects, and facilitating rehabilitation. This is 
the first trial to examine the herbal therapy of combined yunzhi and danshen on quality of life 
among breast cancer patients.
Methods: A multicenter, longitudinal, and self-control study was used. Eighty-two breast cancer 
patients were given combined yunzhi and danshen capsules for six months on a daily basis. Data 
collection including quality of life, vitality status and adverse effects were taken.
Results: Results showed a significant improvement in physical function, role-physical, role-
emotion and health transition (P , 0.05). Patients also reported less fatigue, better quality of 
sleep, better appetite, more regular bowel movements and more stable emotions (P , 0.05). 
As far as side-effects were concerned, only mild discomforts including sore throat (13.4%) and 
dry mouth (9.8%) were recorded.
Conclusion: The findings add clinical evidence to support the beneficial effects of herbal 
therapy on quality of life and vitality status in breast cancer patients. Therefore, herbal therapy 
has a potentially important role to play in managing psychological distress in cancer patients. 
This study also suggests that herbal therapy is clinically acceptable and can be used safely with 
breast cancer patients.
Keywords: complementary therapies, dietary supplements, breast cancer, quality of life, 
adverse effects
Background
Breast cancer remains the most common form of cancer to affect women.1 While cancer 
itself is a life-threatening disease, treatments for cancer can produce very unpleasant 
complications and side effects, including fatigue, anxiety, menopausal symptoms, 
nausea, lymphedema, and dermatitis. Such complications result in poor psychologi-
cal adjustment, vitality status and quality of life.2 Mounting evidence indicates that 
herbal therapy is effective in alleviating anxiety, lessening cancer treatment-related 
side-effects, and facilitating rehabilitation.2–4 The mushrooms yunzhi (Coriolus 
  versicolor) and danshen (Salviae miltiorrhiza) are two commonly-used herbs for 
cancer   prevention.5 The results of clinical trials have further shown that the addition of 
yunzhi to radiotherapy and chemotherapy treatment for cancer patients could greatly 
improve their clinical symptoms and stabilize their immune function, thus greatly 
improving their quality of life.5–8 However, methodological flaws in these studies, 
including a small sample size, have limited the generalizability of their findings. 
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substantial. In 1996, a preclinical study showed that danshen 
had an antioxidative effect which could promote the immune 
system indirectly so as to facilitate rehabilitation and improve 
the quality of life in patients with cancer.9,10 Using danshen as 
a supplement may further promote the immunomodulatory 
activities of yunzhi.
Our previous studies on the immunity of combined yunzhi 
and danshen (YZDS) in breast cancer patients have shown 
that a 6-month treatment with YZDS capsules could be 
beneficial for immunomodulatory functions by significantly 
enhancing cell-mediated immunity and humoral immunity 
in individuals whose immune systems might be suppressed 
by radiotherapy, chemotherapy, or estrogen replacement 
therapy.11 The findings of this study were consistent with 
the conclusions of a review article that yunzhi and danshen 
had a beneficial effect on immunology.5–7,9,12 A more recent 
double-blind, randomized, placebo-control study found 
that combined YZDS significantly improved the physical 
well-being and immune status of both healthy participants 
and patients with nasopharyngeal carcinoma.12,13 The aim 
of this study is to further explore the effect of YZDS on the 
vitality status, quality of life, and safety profile of patients 
with breast cancer.
Methods
study setting and samples
This was a multicenter, longitudinal, pre–posttreatment self-
control study. Patients who had completed cancer treatments 
(surgery, radiotherapy, chemotherapy) within the past 3 years 
were recruited from breast cancer centers at a university-
affiliated hospital, government hospitals and private clinics. 
To be included in the study, the patients had to be Chinese 
females aged $30, stage I–III breast cancer according to the 
TNM Classification of Malignant Tumors by the International 
Union Against Cancer and the   American Joint Committee on 
Cancer (AJCC) Stage Grouping designated by the AJCC,14 
and who were not receiving any concurrent medical treat-
ment. Patients were excluded if they had cancer in both 
breasts or cancer metastases were present, had abnormal liver 
and renal function, were either pregnant or breastfeeding, had 
a significant history of drug hypersensitivity, or were taking 
other alternative medicine or supplements. Based on previous 
studies, there is a 7%–10% difference in the quality of life 
between women with and without breast cancer.15,16 Taking 
a conservative approach, an 11% increase in the quality of 
life was used as the primary outcome. Eighty-two patients 
were required in order to detect group differences at a 5% 
two-sided significance level with a power of 90% and an 
attrition rate of 20%.
Procedure
Ethical approval for this study was obtained from the involved 
university and hospitals. Eligible patients who were referred 
by the collaborating hospitals and clinics were invited to 
participate in the study. After written consent was obtained, a 
baseline assessment (V1) of vitality status and quality of life 
was made. Patients then received 6-month YZDS treatment 
on a daily basis, taking 4 capsules 3 times a day. Checks were 
made at the 8th week (V2) and 16th week (V3), to ensure that 
the patients were on the right regime. At the 24th week (V4) 
patients attended a research clinic for a post-test assessment 
of vitality status, quality of life, and safety profile. Patients 
were asked to keep a diary recording their drug compliance 
and any side effects, and these diaries were collected at these 
three points. Figure 1 outlines the overall study protocol.
Auditing of adverse effects is less well-established in 
complementary and alternative medicine, including Chinese 
medicine, than in primary medicine. Very few studies have 
examined the rate of adverse effects, and the only documenta-
tion available consists of isolated case reports.17 This being 
the case, we were particularly interested in including an 
assessment of adverse effects as one of the objectives of this 
study. All subjects were asked whether they had experienced 
any discomfort or adverse events, by means of an open-ended 
question at each study visit. Particular instances of discomfort 
or adverse events were then sorted into 3 categories: ‘Hot 
Constitution’ for complaints such as cold sore or sore throat; 
‘Cold Constitution’ for dizziness or diarrhea; and ‘Others’ 
for vomiting or stomach discomfort. This classification was 
suggested by a Chinese medicine practitioner and based on 
established terminology used in Chinese medical literature.18 
Blood tests were carried out to assess renal and liver function 
and to ensure that the YZDS treatment was not endangering 
patients’ safety. Serious adverse events were recorded in the 
serious adverse events form and reported within 24 hours to 
the Ethics Committee.
interviewing instrumentation
The Cantonese version of the SF-36 Health Survey question-
naire was used to evaluate the change in quality of life.19,20 Its 
36 items are divided into 9 domains measuring (1) physical 
functioning with range 10–30, (2) role-physical with range 
4–8, (3) bodily pain with range 2–12, (4) general health 
with range 5–25, (5) vitality with range 4–24, (6) social Patient Preference and Adherence 2010:4
Identification of eligible participants 
University-affiliated hospital 
Government hospital 
Private clinics 
Recruitment of participants 
0th week (V1) 
Pretest data 
8th week (V2)
Compliance checking 
16th week (V3) 
Compliance checking 
24th week (V1) 
Post-test data 
Figure 1 study protocol.
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  functioning with range 2–10, (7) role-emotional with range 
3–6, (8) mental health with range 5–30, and (9) health 
transition with range 1–5. The raw scale scores in the first 
8 domains were transferred into a 0%–100% scale, where 
higher percentage scores in each of the domains represented a 
better quality of life. The raw scale score in the health transi-
tion domain was directly presented with a lower scale score 
indicating a better subjective feeling of health status.
Five aspects of vitality status were used namely level of 
fatigue, appetite, bowel movement pattern, sleeping quality, 
and emotion status. These scores ranged from 1–7 for   measures 
of the above 5 aspects, with higher scores   representing a   better 
vitality. The vitality status questionnaire was reviewed by 
an expert panel including 2 Chinese medicine practitioners, 
2 physicians, 2 nurses, and 1 epidemiologist.
statistical analyses
The SPSS statistical package (version 13.0 for Windows; 
SPSS Inc., Chicago, IL) was used for data entry and analysis. 
Intention to treat using the mean within the group was applied 
to replace the missing data. Demographics data was presented 
by descriptive statistics. The outcome measures on quality of 
life and vitality status between pre- and post-treatment over 
6 months were compared using paired t-test in parametric Patient Preference and Adherence 2010:4
Table  1  Demographics  of  breast  cancer  subjects  in  YZDs   
clinical trial
Demographics Category Frequency
Age (years) Mean (sD) 45.6 (6.81) 
Period of breast cancer diagnosis 
before entering the study  
(weeks)
Mean (sD) 56 (28.32) 
Period of completion of  
anti-cancer treatment (weeks)
Mean (sD) 31.7 (27.7) 
stage of breast cancer (%) stage i 29.3
stage ii 62.2
stage iii 8.5
Location of breast cancer (%) Left breast 47.6
right breast 52.4
Anti-cancer treatment (%) surgery 100.0
chemotherapy 78.0
radiotherapy 74.4
Anti-estrogen 
therapy 
(Tamoxifen)
70.7
Table  2  effect  of  YZDs  on  breast  cancer  subjects  in  YZDs 
clinical trial
Parameter 
(n = 82 with ITT)
Pretest mean 
(mean ± SD)
Posttest mean 
(mean ± SD)
Treatment 
effect 
(P-value)
Vitality
  Exercise frequency 5.76 ± 3.40 6.13 ± 4.41 0.349
  Fatigue level 4.45 ± 1.26 2.55 ± 1.25 ,0.001*
  sleeping pattern 4.44 ± 1.33 5.15 ± 1.21 ,0.001*
  Appetite 5.61 ± 1.23 6.04 ± 1.13 ,0.001*
  Bowel movement 4.88 ± 1.44 5.44 ± 1.27 ,0.001*
  emotional status 4.54 ± 1.37 5.04 ± 1.25 ,0.001*
QoL
  Physical function 86.77 ± 11.64 92.74 ± 8.09 ,0.001*
  role-physical 58.54 ± 37.93 68.90 ± 36.12 0.029*
  Bodily pain 28.78 ± 21.51 24.15 ± 21.43 0.074
  general health 50.06 ± 11.64 49.76 ± 10.45 0.856
  Vitality 56.46 ± 10.56 56.65 ± 9.78 0.894
  social function 47.41 ± 11.24 49.54 ± 7.47 0.104
  role-emotion 57.72 ± 39.56 70.33 ± 34.34 0.008*
  Mental health 59.41 ± 10.02 59.80 ± 8.95 0.772
  health transition 2.84 ± 1.25 2.05 ± 0.94 ,0.001*
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data and Wilcoxon signed-rank test in nonparametric data. 
Regression model was also used to explore the relationship 
between   intervention effects and period since breast cancer 
diagnosis. Adverse event data was presented descriptively.
Results
Baseline characteristics  
of the participants
Between June and October 2002, 82 breast cancer patients 
were admitted to the study of whom 78 completed the 
6-month study. Four patients withdrew from the study, two 
because they did not believe that YZDS would have any 
beneficial effect, one who was afraid of the blood test for 
the safety profile, and one who was afraid of contracting 
Severe Acute Respiratory Syndrome (SARS). Intention to 
treat using the fairest approach of mean replacement was 
applied and data of all 82 participants were included for data 
analysis. The mean age of the participants was 45.6 years 
(SD = 6.8). The mean period since cancer diagnosis and anti-
cancer treatment completion was 56.0 weeks (SD = 28.3) and 
31.7 weeks (SD = 27.7) respectively. Most of the patients 
had been diagnosed with stage II breast cancer (62.2%). As 
far as anticancer treatment was concerned, all patients had 
completed surgery (100%), 78.0% had had chemotherapy 
and completed, 74.4% had had radiotherapy and completed, 
and 70.7% were undergoing antiestrogen replacement 
  (Tamoxifen) for prevention treatment   during the study 
period. The demographics are shown in Table 1.
intervention compliance
The mean compliance rate over the 6-month treatment 
period was 97.0%. Patients were asked to report their 
compliance in the form of diary entries, and a check on the 
reliability of their reports was made by counting the number 
of capsules in the bottles returned in each study visit. The 
agreement between the diary reports and the capsule checks 
was 99.9%.
Intervention effects on quality  
of life and vitality status
Table 2 summarizes the results of the study. As far as qual-
ity of life was concerned, the domains of physical function, 
role-physical, role-emotion and health transition were all 
significantly improved (P , 0.05) after 6-month YZDS 
treatment. No significant change was found in the domains 
of bodily pain, general health, vitality, social function, and 
mental health. Further analysis of the relationship between 
intervention effects and period since breast cancer diagnosis 
using regression found no significant difference.
The vitality status findings were consistent with the 
quality of life using the SF-36 Health Survey questionnaire: 
participants experienced less fatigue (P , 0.001), better 
quality of sleep (P , 0.001), better appetite (P , 0.001), 
more regular bowel movements (P , 0.001) and more 
stable emotion (P , 0.001). Repeated analysis in respect of Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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period since breast cancer diagnosis also found no significant 
  difference in the change of vitality status.
Adverse events related  
to the intervention
None of the participants reported any serious adverse events 
during the 6-month study period. Only mild discomforts were 
recorded, and these are shown in Table 3. The most common 
discomforts were sore throat (13.4%) and dry mouth (9.8%) 
under the category of Hot Constitution.
There was no significant change in different parameters 
of the renal function test (sodium, potassium, urea creatinine) 
and liver function test (total protein, albumin, total bilirubin, 
alkaline phosphate, alanine transaminase) during the study 
period. All these parameters were generally within the normal 
range both before and after study.
Discussion
This study was the first trial to assess the effect of treatment 
with Chinese medicine on the quality of life of patients with 
breast cancer which strictly followed good clinical practice 
(GCP). The findings support the therapeutic effect of a com-
bined treatment of YZDS on quality of life and vitality status. 
Rising stress levels make it very difficult for cancer patients 
to care for themselves, thereby causing many psychological 
and physical problems and placing a burden on health care 
costs. Yet the evidence suggests that a significant reduction 
in and management of disease- and treatment-related symp-
toms could improve the quality of life among women with 
breast cancer.16 Therefore, herbal therapy has a potentially-
important role to play in managing psychological distress 
in cancer patients. This study also suggests that this herbal 
therapy is clinically acceptable and can be used safely with 
breast cancer patients.
The conspicuous success of herbal therapy in improving 
the quality of life of breast cancer patients can be explained 
by its favorable effects on the immune functions.11,12,21 These 
findings conform to those of polysaccharide peptide (PSP) 
studies on the quality of life in patients with gynecological 
malignancies.22 The significant improvement in vitality sta-
tus, including fatigue level, quality of sleep, appetite, bowel 
movement, and emotion status, is also in line with the results 
of a PSP study by Chai and Shen.23
Although YZDS treatment might have been expected to 
enhance the domains of general health, vitality, and mental 
health in the SF-36 survey, the current study indicates the 
absence of such improvement in breast cancer patients. This 
observation may be explained by the sensitivity of the SF-36 
questionnaire, which is designed to evaluate the efficacy 
of conventional treatment and may be unable to assess the 
positive psychological effects of herbal therapy in explicit 
terms. Nevertheless, as a significant trend of improvement 
in vitality status was found when the vitality questionnaire 
derived by an expert panel of Chinese medicine practitio-
ners was used, the beneficial effect of YZDS should not be 
undermined.
Although the current study adopted a specially-designed 
vitality questionnaire to evaluate the effect of herbal therapy, 
the absence of a control group leaves open the possibility 
that its positive findings are attributable to the placebo effect 
of herbal therapy. Also, the vitality questionnaire needs to 
be further studied for its reliability. In this respect, the low 
power of the current study in detecting the intervention effect 
should be taken into account. Herbal therapy is becoming an 
increasingly-popular treatment method, and it is possible that 
its effect on the quality of life of some patients was exag-
gerated because they placed high confidence in its effective-
ness. Although the possibility of a placebo effect cannot be 
entirely ruled out, the immunological results of the current 
study,11 its broad sample source, its low dropout rate, and 
its good compliance rate may not limit the generalizability 
of the findings.
The study design had two limitations. It was originally 
designed as a double-blind placebo-control cross-over 
study, but it proved very difficult to persuade participants 
at risk from a life-threatening disease to observe the condi-
tions of the study. The use of a placebo was a particular 
stumbling block. As nearly all the participants were afraid 
of a recurrence of cancer, 97% of them breached the terms 
of the study by taking their own herbal supplements, and 
over half (60%) were found to be taking 2 or more types 
Table 3 Mild adverse events of breast cancer subjects in YZDs 
clinical trial
Adverse events Cases (%)
Hot Constitution 25 (30.5)
  sore throat 11 (13.4)
  gum sore 2 (2.4)
  Dry mouth 8 (9.8)
  Acne 2 (2.4)
  insomnia 2 (2.4)
Cold Constitution 1 (1.2)
  Diarrhea 1 (1.2)
Other 5 (6.1)
  stomach discomfort 5 (6.1)Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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of health supplement at the same time. The scale of this 
subversive behavior became apparent 4 months after the 
commencement of the study. We decided that the best and 
most practical course of action was to convert the study into 
a self-control   comparative study without placebo, to ensure 
that the participants would comply with the study protocol. 
After we modified the study design, 97% of the participants 
promised to stop taking their own herbal supplements 
during a 1-month washout period and restart the 6-month 
clinical trial. Although such an open-label outcome study 
is obviously of lower research value by modern medicine 
standards and is not a substitute for the double-blind placebo 
methodology, it fulfilled an important role in defining the 
variables in the clinical use of Chinese medicine. Another 
limitation is the lack of information on the menstruation 
status of participants which might be important adjusted 
factors in exploring the relationship between the herbal 
effect and the quality of life among breast cancer patients 
receiving Tamoxifen. It should be taken into consideration 
in any future studies.
Conclusion
Psychological distress and poor quality of life is a serious 
problem that significantly affects the morbidity of breast 
cancer patients. Herbal therapy seems to offer a useful 
complementary treatment that can enhance the health 
outcome of this group of patients. This study, using self-
control design, is the first step to explore the efficacy of 
herbal therapy on quality of life in breast cancer patients. 
Results from the outcome studies could provide evidence 
for efficacy and might be used to design more future com-
prehensive studies.
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